- Home
- INSW vs RARE Comparison
INSW vs RARE Comparison
Compare INSW & RARE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | INSW | RARE |
|---|---|---|
| Founded | 1999 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.8B | 2.3B |
| IPO Year | N/A | 2014 |
Fundamental Metrics
Financial Performance| Metric | INSW | RARE |
|---|---|---|
| Price | $57.21 | $24.23 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 19 |
| Target Price | $48.00 | ★ $73.11 |
| AVG Volume (30 Days) | 531.7K | ★ 4.2M |
| Earning Date | 02-26-2026 | 02-12-2026 |
| Dividend Yield | ★ 5.13% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 4.39 | N/A |
| Revenue | ★ $770,036,000.00 | $630,598,000.00 |
| Revenue This Year | N/A | $19.68 |
| Revenue Next Year | $3.69 | $19.44 |
| P/E Ratio | $13.00 | ★ N/A |
| Revenue Growth | N/A | ★ 20.63 |
| 52 Week Low | $27.20 | $18.41 |
| 52 Week High | $58.98 | $46.50 |
Technical Indicators
Market Signals| Indicator | INSW | RARE |
|---|---|---|
| Relative Strength Index (RSI) | 65.92 | 42.79 |
| Support Level | $55.83 | $22.00 |
| Resistance Level | $58.98 | $24.65 |
| Average True Range (ATR) | 1.96 | 1.24 |
| MACD | 0.41 | 0.40 |
| Stochastic Oscillator | 84.56 | 75.77 |
Price Performance
Historical ComparisonAbout INSW International Seaways Inc.
International Seaways Inc owns and operates a fleet of oceangoing vessels engaged in the transportation of crude oil and petroleum products. The company's vessel operations are organized into two segments: Crude Tankers and Product Carriers. The fleet consists of ULCC, VLCC, Suezmax, Aframax, and Panamax crude tankers, as well as LR1, LR2, and MR product carriers.
About RARE Ultragenyx Pharmaceutical Inc.
Ultragenyx Pharmaceutical Inc is a USA-based biopharmaceutical company. It identifies, acquires, develops, and commercializes novel products for the treatment of serious rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases. The company's medicine portfolio includes Crysvita, Dojolvi and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients 1 year of age and older. Mepsevii is indicated in pediatric and adult patients for the treatment of Mucopolysaccharidosis VII.